Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

FUJIFILM

Financial Results (Consolidated) for Six Months Ended September 30, 2026

FUJIFILM Holdings Corporation

November 9, 2026

Teiichi Goto
President and Chief Executive Officer
URL: https://holdings.fujifilm.com/en

Projected date of Interim report: November 13, 2026 Projected date of the beginning of cash dividends: December 2, 2026

Reference materials regarding operating results of the current quarter to be prepared: Yes

Meeting to explain operating results of the current quarter to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

1. Results of Six Months Ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
		%		%		%		%
Six months ended Sept. 30, 2026	1,711,514	8.8	141,168	(10.9)	142,303	(12.1)	105,226	(12.5)
Six months ended Sept. 30, 2025	1,572,363	3.8	158,486	16.9	161,914	15.3	120,232	9.0

Note: Comprehensive income

Six months ended September 30, 2026 ¥50,858 million (-73.2%) Six months ended September 30, 2025 ¥189,476 million (699.6%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)
	Yen	Yen
Six months ended Sept. 30, 2026	87.94	87.86
Six months ended Sept. 30, 2025	99.79	99.70

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets
				%
Six months ended Sept. 30, 2026	6,102,751	3,820,789	3,815,788	62.5
As of March 31, 2026	6,053,776	3,844,385	3,839,550	63.4

2. Cash Dividends

	Cash dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2026	-	35.00	-	35.00	70.00
Year ending March 31, 2027	-	37.50			
Year ending March 31, 2027 (Forecast)			-	37.50	75.00

Note: Changes in dividends forecast during the quarter under review: None

3. Forecast for the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen
%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
		%		%		%		%	Yen
For the Year ending March 31, 2027	3,590,000	6.9	365,000	4.2	375,000	2.3	280,000	1.2	234.10

Note: Changes in forecast which was recently announced: Yes

Note: Net income attributable to FUJIFILM Holdings per share is calculated using the number of shares issued as of September 30, 2026 excluding treasury shares for the average number of shares for the relevant period.

Notes

(1) Changes in Status of Material Subsidiaries during the Current Consolidated Six Months: None

(2) Adoption of simplified method of accounting or specific accounting treatments: None

(3) Changes in accounting principles

1. Changes in accounting policies accompanied by revisions of accounting standards: None
2. Changes in accounting policies other than 1. above: None

(4) Number of shares outstanding

1. Issued (including treasury stock):	As of Sept. 30, 2026	1,234,150,284	As of March 31, 2026	1,243,877,184
2. Treasury stock:	As of Sept. 30, 2026	38,066,444	As of March 31, 2026	38,547,368
3. Average number of shares:	Six months ended Sept. 30, 2026	1,195,051,394	Six months ended Sept. 30, 2025	1,203,610,623

This report is not reviewed.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have an intention of guaranteeing the realization of the forecasts. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecasts and warnings for users of the forecasts are mentioned in the page 6, (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results in 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER.

[INDEX]

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER …… P.2
(1) Explanation on Consolidated Operating Results ……... P.2
(2) Explanation on the Consolidated Financial Position ……. P.5
(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results …… P.6
2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION ……. P.7
(1) Changes in Status of Material Subsidiaries during the Current Consolidated Six Months.…… P.7
(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments ……... P.7
(3) Changes in Accounting Principles ……..... P.7
3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION ... P.7
4. CONSOLIDATED FINANCIAL STATEMENTS ……..…… P.8
(1) Consolidated Balance Sheets …… P.8
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income ... P.10
(Consolidated Statements of Income) ……...…… P.10
Six months ended September 30 ……...…… P.10
Three months ended September 30……...…… P.11
(Consolidated Statements of Comprehensive Income)……..……. P.12
Six months ended September 30……...…… P.12
Three months ended September 30……. P.12
(3) Consolidated Statements of Cash Flows …… P.13
(4) Notes to Consolidated Financial Statements …… P.14
(Note Relating to the Going Concern Assumption) …….. P.14
(Segment Information) …….. P.14
1) Six months ended September 30 …….. P.14
2) Three months ended September 30……..…… P.17
(Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity) ……..... P.17
(Significant Subsequent Events) …… P.17

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER

(1) Explanation on Consolidated Operating Results

Amount Unit: Billions of yen

	Six months ended September 30, 2026		Six months ended September 30, 2025		Change (Amount)	Change (%)
Domestic revenue	31.2%	533.4	35.0%	550.0	(16.6)	(3.0%)
Overseas revenue	68.8%	1,178.2	65.0%	1,022.4	155.8	15.2%
Revenue	100.0%	1,711.5	100.0%	1,572.4	139.2	8.8%
Operating income	8.2%	141.2	10.1%	158.5	(17.3)	(10.9%)
Income before income taxes	8.3%	142.3	10.3%	161.9	(19.6)	(12.1%)
Net income attributable to FUJIFILM Holdings	6.1%	105.2	7.6%	120.2	(15.0)	(12.5%)
Exchange rates (Yen / US$)		¥159		¥146		¥13
Exchange rates (Yen / Euro)		¥184		¥168		¥16

In the consolidated six months ended September 30, 2026, the Fujifilm Group recorded consolidated revenue of ¥1,711.5 billion (up 8.8% year-over-year), reflecting revenue increases mainly in the Medical Systems, Semiconductor Materials and Imaging businesses.

Operating income decreased to ¥141.2 billion (down 10.9% year-over-year) despite higher earnings in the Electronics and Imaging segments, primarily due to increased fixed costs in the Bio CDMO business in the Healthcare segment, one-time costs incurred to strengthen the organizational structure of the Business Innovation segment, and the impact of rising raw material costs. Consolidated income before income taxes amounted to ¥142.3 billion (down 12.1% year-over-year), and consolidated net income attributable to FUJIFILM Holdings amounted to ¥105.2 billion (down 12.5% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during the first half of this fiscal year were ¥159 and ¥184, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Six months ended September 30, 2026	Six months ended September 30, 2025	Change (Amount)	Change (%)
Healthcare	554.1	499.2	54.9	11.0%
Electronics	259.6	209.5	50.2	23.9%
Business Innovation	566.7	572.2	(5.5)	(1.0%)
Imaging	331.1	291.5	39.5	13.6%
Consolidated Total	1,711.5	1,572.4	139.2	8.8%

Operating Income (Loss) by Operating Segment

Amount Unit: Billions of yen

Segment	Six months ended September 30, 2026	Six months ended September 30, 2025	Change (Amount)	Change (%)
Healthcare	3.4	23.7	(20.3)	(85.8%)
Electronics	63.5	42.0	21.6	51.3%
Business Innovation	(0.6)	31.4	(31.9)	-
Imaging	93.5	80.4	13.1	16.2%
Corporate Expenses etc.	(18.6)	(18.9)	0.3	-
Consolidated Total	141.2	158.5	(17.3)	(10.9%)

Healthcare

In the Healthcare segment, consolidated revenue amounted to ¥554.1 billion (up 11.0% year-over-year).

Consolidated operating income amounted to ¥3.4 billion (down 85.8% year-over-year).

The Medical Systems business posted higher revenue. Sales of endoscopes continued to increase in key markets, including Japan, the U.S. and Europe. Medical IT sales also grew, with steady sales of systems and services, mainly for the *SYNAPSE* Picture Archiving and Communication System (PACS), in Europe, the Middle East and other markets, and strong sales of ultrasound diagnostic equipment in Japan and Europe. Furthermore, as new products developed using AI technology, in July 2026, we launched new models of permanent magnet open MRI systems, the *0.4 Tesla APERTO Lucent ff* and the *0.3 Tesla AIRIS Vento ff*, which provide improved image quality and workflow efficiency. In August 2026, we launched the *FBD Coaccula* X-ray bone densitometer, which helps streamline bone density testing workflows through its automated analysis function. We will continue to leverage our proprietary technologies to provide a wide range of products and services that meet the diverse needs of medical settings, thereby contributing to further improvements in diagnostic efficiency and the quality of healthcare, as well as maintaining and promoting people's health.

In the Bio CDMO business, although small- to medium-scale facilities were affected by voluntary shutdowns in response to regulatory inspections (operations had resumed as of the end of September 2026), revenue increased for the business as a whole, driven by strong operations at the large-scale facilities in the Denmark site as well as the ramp-up of operations at the North Carolina site in the U.S., which opened in the previous fiscal year. In addition, in the ADC (antibody-drug conjugate) field, where growth is expected, we are working to establish an integrated contract manufacturing framework covering antibody manufacturing, drug conjugation, formulation and packaging by leveraging our extensive experience and technologies in areas including process development and manufacturing of antibody drugs, synthetic chemistry and the handling of highly potent active pharmaceutical ingredients. As part of this initiative, in August 2026, we entered into a strategic partnership with Taiho Pharmaceutical Co., Ltd. to develop manufacturing technologies for next-generation ADCs.

The LS (Life Sciences) Solutions business[*1] posted higher revenue. In the Life Sciences business, sales of culture media increased, driven by greater use of our culture media by major pharmaceutical companies, while sales of iCell (iPS cell-derived differentiated cells) for drug discovery support remained strong amid robust demand for drug discovery. In the Consumer Healthcare business, sales of cosmetics and supplements were also strong.

[*1] The LS Solutions business comprises the Life Sciences, Pharmaceutical, Consumer Healthcare and CRO (Contract Research Organization) businesses.

Electronics

In the Electronics segment, consolidated revenue amounted to ¥259.6 billion (up 23.9% year-over-year).

Consolidated operating income amounted to ¥63.5 billion (up 51.3% year-over-year).

The semiconductor market is experiencing significant growth, particularly in advanced semiconductors, against the backdrop of rapidly expanding AI-related demand. By steadily capturing demand for advanced materials used in AI semiconductors, sales in our Semiconductor Materials business increased significantly in both the logic and memory fields, as sales to major foundries remained strong, while sales to major semiconductor manufacturers in the U.S., South Korea and Europe recovered. Regarding front-end materials, driven by miniaturization and the increasing number of interconnect layers, sales increased significantly for our copper interconnect CMP slurry and NTI developers, both of which hold the top global market share, as well as for post-CMP cleaners, used as cleaning agents for CMP slurries, and advanced photoresists. With respect to back-end materials, sales of *ZEMATES* (liquid-type polyimide) for interlayer insulation films grew significantly, driven by expanding demand for advanced packaging for AI semiconductors. In August 2026, a new production facility for post-CMP cleaners began operations at the Oita Factory. Post-CMP cleaners are used in the polishing process for planarizing semiconductor surfaces, a process essential to enhancing semiconductor performance. Through this investment, we will triple our production capacity for post-CMP cleaners used in advanced semiconductors, including AI semiconductors, for which demand is growing rapidly, and further expand our business. In September 2026, we signed a memorandum of understanding (MOU) with Tata Electronics Private Limited, a prominent global player in the electronics manufacturing industry, to strengthen our partnership toward establishing a semiconductor materials production system and supply chain in India. Through this "Make in India" initiative, under which we will establish a local factory through a phased investment of approximately INR8.0 billion (approx. ¥13.0 billion) and strengthen our supply capabilities in India, we will contribute to further accelerating the development of India's semiconductor

materials ecosystem.

The AF (Advanced Functional) Materials business posted higher revenue driven by strong sales of data tapes to major IT companies, amid increasing data volumes associated with the widespread adoption of AI. In September 2026, we launched *FUJIFILM Prescale Motion*, a dynamic surface pressure sensor system that visualizes in real time how pressure is applied from the start to the end of the pressurization process. We will continue to contribute to improving and stabilizing our customers' manufacturing quality by providing products centered on the visualization and quantification of inspection data, thereby promoting the digitalization and greater efficiency of inspection operations at development and manufacturing sites.

Business Innovation

In the Business Innovation segment, consolidated revenue amounted to ¥566.7 billion (down 1.0% year-over-year).

Consolidated operating loss amounted to ¥0.6 billion.

The Business Solutions business posted revenue largely on par with the same period of the previous fiscal year, as solid performance in overseas ERP system sales and implementation support services, among other factors, offset the absence of the special demand for local governments in Japan and overseas BPO services seen in the same period of the previous fiscal year.

The Office Solutions business posted lower revenue mainly due to a decline in exports to Europe and the U.S. as well as lower sales in China. To improve efficiency across the entire maintenance process, we developed an integrated maintenance support platform equipped with AI capabilities and began rolling it out in Japan, the Asia-Pacific region, Europe and the U.S. from July 2026. Going forward, we will continuously enhance and expand the platform's AI capabilities, enabling customer engineers worldwide to deliver high-quality maintenance services and thereby contributing to the stable operation of customers' equipment and improved business continuity.

The Graphic Communications business posted higher revenue, driven in part by increased sales of inkjet printheads in the inkjet field. In September 2026, we announced the transfer of the production and sales functions for printing-plate materials in regions excluding Japan, the U.S., Canada and Mexico to Huangshan Jinruitai Technology Co., Ltd., a printing-plate materials manufacturer based in China, and its affiliates. Going forward, in the printing-plate materials business, we will focus on production in Japan and sales in the Japanese and North American markets.

Additionally, in August 2026, the Company announced that it had begun the assessment of strategic options for the Business Innovation segment, including a partial spin-off. Given the Business Innovation segment's strong earnings base and high cash-generating capability, we will continue to explore these options to enable more agile decision-making going forward, thereby achieving further growth and enhancing corporate value.

Imaging

In the Imaging segment, consolidated revenue amounted to ¥331.1 billion (up 13.6% year-over-year).

Consolidated operating income amounted to ¥93.5 billion (up 16.2% year-over-year).

The Consumer Imaging business posted higher revenue, driven by increased sales of the *instax* instant photo system. In addition to strong sales of mid- to high-priced products such as i*nstax mini Evo* and *instax WIDE 400*, film sales increased as a result of expanded production capacity. In September 2026, we launched *instax Pal 2*, a successor to the palm-sized *instax Pal* with a completely revamped design and features, as well as *instax Link WIDE 2*, a new smartphone printer, both of which have been well received globally. Furthermore, *QuickSnap* marked the 40th anniversary of its launch in July 2026, and we released a new product for the first time in 20 years. We will continue to enhance the value of the experience from capturing images to printing them through *instax* and *QuickSnap*, while contributing to the development of photographic culture that fosters communication between people and supports self-expression.

The Professional Imaging business posted revenue largely on par with the same period of the previous fiscal year, as persistent demand across regions supported solid sales despite the impact of the successive launches of new digital camera products in the same period of the previous fiscal year. Going forward, we will continue to pursue outstanding image quality through large-format sensors in the *GFX serie*s, while further refining the balance of high image quality, compactness and light weight in the *X series*. Furthermore, by creating products that offer new value and shooting experiences, such as *FUJIFILM GFX100RF*, *X half* and *FUJIFILM GFX ETERNA 55*, we will

continue to offer compelling products to a broad range of customers, from digital camera users to professionals in the imaging industry.

(2) Explanation on the Consolidated Financial Position

At the end of the six months ended September 30, 2026, total assets increased by ¥49.0 billion compared with the end of the previous fiscal year (March 31, 2026) to ¥6,102.8 billion, mainly due to increases in property, plant and equipment. Total liabilities increased by ¥72.6 billion to ¥2,282.0 billion. FUJIFILM Holdings shareholders' equity decreased by ¥23.8 billion to ¥3,815.8 billion. As a result, the current ratio decreased by 11.2 percentage points to 125.4%, the debt-equity ratio increased by 2.3 percentage points to 59.8%, and the equity ratio decreased by 0.9 percentage points to 62.5% compared with the end of the previous fiscal year. The Company is maintaining a stable level of asset liquidity and a sound capital structure.

(Cash Flows)

Amount Unit: Billions of yen

	Six months ended September 30, 2026	Six months ended September 30, 2025	Change
Net cash provided by operating activities	195.1	199.1	(4.1)
Net cash used in investing activities	(231.7)	(268.4)	36.7
Net cash provided by (used in) financing activities	11.2	60.4	(49.1)

During the consolidated six months ended September 30, 2026, net cash provided by operating activities totaled ¥195.1 billion. Net cash used in investing activities amounted to ¥231.7 billion, mainly due to the purchases of property, plant and equipment. Thus, free cash flow, or the sum of cash flows from operating and investing activities, was negative ¥36.6 billion. Net cash provided by financing activities amounted to ¥11.2 billion, due to an increase in long-term debts and other factors.

As a result, cash and cash equivalents at the end of the six months ended September 30, 2026 amounted to ¥145.9 billion, down ¥24.7 billion from the end of the previous fiscal year (March 31, 2026).

(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results
(Consolidated financial forecast for the fiscal year ending March 31, 2027)

Amount Unit: Billions of yen

	Previous Forecast (A) (announced on Aug. 6, 2026)	Revised Forecast (B)	Change (B-A)	Change (%)	(Reference) Actual Result for Fiscal Year ended March 31, 2026
Revenue	3,560.0	3,590.0	30.0	0.8%	3,357.0
Operating income	365.0	365.0	-	-	350.2
Income before income taxes	375.0	375.0	-	-	366.6
Net income attributable to FUJIFILM Holdings	280.0	280.0	-	-	276.7
Net income attributable to FUJIFILM Holdings per share	¥234.19	¥234.10	(¥0.09)	(0.0%)	¥229.65
ROE (%)	7.8	7.8	-	-	7.7
ROIC (%)	5.6	5.6	-	-	5.5
Exchange rates (Yen / US$)	¥156	¥157	¥1	-	¥151
Exchange rates (Yen / Euro)	¥181	¥180	¥(1)	-	¥175

For the fiscal year ending March 2027, the Company has revised its consolidated revenue upward to ¥3,590.0 billion (up 0.8% from the previous forecast) reflecting strong sales in the Medical Systems and Semiconductor Materials businesses. Operating income is expected to remain unchanged from the previous forecast at ¥365.0 billion, as an expected increase in profit in the Electronics segment is offset by factors including a decrease in gross profit associated with lower revenue in the Business Innovation segment. Income before income taxes is forecast at ¥375.0 billion, and net income attributable to FUJIFILM Holdings at ¥280.0 billion.

The projected currency exchange rates for the U.S. dollar and the euro against the yen for the full year are ¥157 and ¥180, respectively.

2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION

(1) Changes in Status of Material Subsidiaries during the Current Consolidated Six Months:

None.

(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments:

None.

(3) Changes in Accounting Principles:

None.

3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION:

None.

4. CONSOLIDATED FINANCIAL STATEMENTS

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of September 30, 2026	As of March 31, 2026	Change
ASSETS			
Current assets:			
Cash and cash equivalents	145,865	170,553	(24,688)
Notes and accounts receivable:			
Trade	650,222	742,721	(92,499)
Lease receivables	30,113	31,750	(1,637)
Affiliated companies	2,601	2,737	(136)
Allowance for credit losses	(13,354)	(14,693)	1,339
	669,582	762,515	(92,933)
Inventories	662,267	600,796	61,471
Prepaid expenses and Other	218,901	185,169	33,732
Total current assets	1,696,615	1,719,033	(22,418)
Investments and long-term receivables:			
Investments in and advances to affiliated companies	37,455	37,617	(162)
Investment securities	43,819	43,672	147
Long-term lease receivables	47,159	49,181	(2,022)
Other long-term receivables	75,961	76,831	(870)
Allowance for credit losses	(1,288)	(1,511)	223
Total investments and long-term receivables	203,106	205,790	(2,684)
Property, plant and equipment:			
Land	120,697	121,419	(722)
Buildings and structures	1,188,124	1,173,654	14,470
Machinery, equipment and others	2,110,712	1,989,906	120,806
Construction in progress	942,748	979,735	(36,987)
	4,362,281	4,264,714	97,567
Less accumulated depreciation	(1,981,816)	(1,956,406)	(25,410)
Total property, plant and equipment	2,380,465	2,308,308	72,157
Other assets:			
Operating lease right-of-use assets	135,075	130,157	4,918
Goodwill, net	983,984	997,068	(13,084)
Other intangible assets, net	141,933	151,175	(9,242)
Other	561,573	542,245	19,328
Total other assets	1,822,565	1,820,645	1,920
Total assets	6,102,751	6,053,776	48,975

Amount Unit: Millions of yen

	As of September 30, 2026	As of March 31, 2026	Change
LIABILITIES			
Current liabilities:			
Short-term debt	383,366	287,913	95,453
Notes and accounts payable:			
Trade	304,660	291,296	13,364
Construction	74,873	97,154	(22,281)
Affiliated companies	1,337	1,399	(62)
	380,870	389,849	(8,979)
Accrued income taxes	49,296	53,202	(3,906)
Accrued liabilities	268,368	280,017	(11,649)
Short-term operating lease liabilities	38,188	36,549	1,639
Other current liabilities	232,608	210,742	21,866
Total current liabilities	1,352,696	1,258,272	94,424
Non-current liabilities:			
Long-term debt	598,554	607,034	(8,480)
Accrued pension and severance costs	24,294	25,515	(1,221)
Long-term operating lease liabilities	98,064	95,517	2,547
Other non-current liabilities	208,354	223,053	(14,699)
Total non-current liabilities	929,266	951,119	(21,853)
Total liabilities	2,281,962	2,209,391	72,571
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 2,400,000,000 shares			
Issued: 1,234,150,284 shares			
Retained earnings	3,160,376	3,117,407	42,969
Accumulated other comprehensive income	681,592	736,167	(54,575)
Treasury stock, at cost	(66,543)	(54,387)	(12,156)
Total FUJIFILM Holdings shareholders' equity	3,815,788	3,839,550	(23,762)
Noncontrolling interests	5,001	4,835	166
Total equity	3,820,789	3,844,385	(23,596)
Total liabilities and equity	6,102,751	6,053,776	48,975

Note: Details of accumulated other comprehensive income (loss)

	As of September 30, 2026	As of March 31, 2026	Change
Foreign currency translation adjustments	639,367	694,154	(54,787)
Pension liability adjustments	42,225	42,013	212

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

Six months ended September 30

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026		Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025		Change	
					Amount	%
	%		%			
Revenue	100.0	1,711,514	100.0	1,572,363	139,151	8.8
Cost of sales:	59.6	1,019,969	59.0	927,028	92,941	10.0
Gross profit	40.4	691,545	41.0	645,335	46,210	7.2
Operating expenses:						
Selling, general and administrative	27.1	464,128	26.0	409,544	54,584	13.3
Research and development	5.0	86,249	4.9	77,305	8,944	11.6
	32.2	550,377	31.0	486,849	63,528	13.0
Operating income	8.2	141,168	10.1	158,486	(17,318)	(10.9)
Other income (expenses):						
Interest and dividend income		6,261		5,924	337	
Interest expense		(4,323)		(2,838)	(1,485)	
Foreign exchange gains (losses), net		(3,917)		(5,362)	1,445	
Gains (losses) on equity securities, net		3,151		(3,341)	6,492	
Other, net		(37)		9,045	(9,082)	
	0.1	1,135	0.2	3,428	(2,293)	(66.9)
Income before income taxes	8.3	142,303	10.3	161,914	(19,611)	(12.1)
Income taxes	2.2	37,751	2.8	43,870	(6,119)	(13.9)
Equity in net earnings of affiliated companies	0.1	930	0.2	2,418	(1,488)	(61.5)
Net income	6.2	105,482	7.7	120,462	(14,980)	(12.4)
Less: Net (income) loss attributable to the noncontrolling interests	0.0	(256)	0.0	(230)	(26)	-
Net income attributable to FUJIFILM Holdings	6.1	105,226	7.6	120,232	(15,006)	(12.5)

Three months ended September 30

Amount Unit: Millions of yen

	Three months ended September 30, 2026 From July 1, 2026 To September 30, 2026		Three months ended September 30, 2025 From July 1, 2025 To September 30, 2025		Change	
					Amount	%
	%		%			
Revenue	100.0	885,021	100.0	822,881	62,140	7.6
Cost of sales:	58.4	516,894	59.6	490,117	26,777	5.5
Gross profit	41.6	368,127	40.4	332,764	35,363	10.6
Operating expenses:						
Selling, general and administrative	26.5	234,179	25.9	212,901	21,278	10.0
Research and development	5.0	43,964	4.5	36,668	7,296	19.9
	31.4	278,143	30.3	249,569	28,574	11.4
Operating income	10.2	89,984	10.1	83,195	6,789	8.2
Other income (expenses):						
Interest and dividend income		3,157		2,812	345	
Interest expense		(2,464)		(385)	(2,079)	
Foreign exchange gains (losses), net		(3,422)		622	(4,044)	
Gains (losses) on equity securities, net		1,173		(2,682)	3,855	
Other, net		1,775		6,398	(4,623)	
	0.0	219	0.8	6,765	(6,546)	(96.8)
Income before income taxes	10.2	90,203	10.9	89,960	243	0.3
Income taxes	2.6	22,597	2.8	23,041	(444)	(1.9)
Equity in net earnings (losses) of affiliated companies	0.0	300	0.0	(280)	580	-
Net income	7.7	67,906	8.1	66,639	1,267	1.9
Less: Net (income) loss attributable to the noncontrolling interests	0.0	(104)	0.0	(174)	70	-
Net income attributable to FUJIFILM Holdings	7.7	67,802	8.1	66,465	1,337	2.0

(Consolidated Statements of Comprehensive Income)

Six months ended September 30

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026	Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025	Change
Net income	105,482	120,462	(14,980)
Other comprehensive income (loss), net of tax:			
Foreign currency translation adjustments	(54,836)	69,379	(124,215)
Pension liability adjustments	212	(403)	615
Unrealized gains on derivatives	-	38	(38)
Total	(54,624)	69,014	(123,638)
Comprehensive income	50,858	189,476	(138,618)
Less: Comprehensive (income) loss attributable to noncontrolling interests	(207)	(324)	117
Comprehensive income attributable to FUJIFILM Holdings	50,651	189,152	(138,501)

Three months ended September 30

Amount Unit: Millions of yen

	Three months ended September 30, 2026 From July 1, 2026 To September 30, 2026	Three months ended September 30, 2025 From July 1, 2025 To September 30, 2025	Change
Net income	67,906	66,639	1,267
Other comprehensive income (loss), net of tax:			
Foreign currency translation adjustments	(105,323)	66,950	(172,273)
Pension liability adjustments	(507)	(192)	(315)
Unrealized gains (losses) on derivatives	-	(2)	2
Total	(105,830)	66,756	(172,586)
Comprehensive income (loss)	(37,924)	133,395	(171,319)
Less: Comprehensive (income) loss attributable to noncontrolling interests	30	(196)	226
Comprehensive income (loss) attributable to FUJIFILM Holdings	(37,894)	133,199	(171,093)

(3) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026	Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025	Change
Operating activities			
Net income	105,482	120,462	(14,980)
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	103,849	81,459	22,390
(Gains) losses on equity securities	(3,151)	3,341	(6,492)
Equity in net (gains) losses of affiliated companies, net of dividends received	(200)	(2,061)	1,861
Changes in operating assets and liabilities:			
Notes and accounts receivable	89,359	50,785	38,574
Inventories	(70,650)	(44,376)	(26,274)
Notes and accounts payable - trade	16,386	6,211	10,175
Changes in other current assets	(18,231)	(11,356)	(6,875)
Accrued income taxes and other liabilities	(8,767)	8,725	(17,492)
Others	(18,995)	(14,043)	(4,952)
Subtotal	89,600	78,685	10,915
Net cash provided by operating activities	195,082	199,147	(4,065)
Investing activities			
Purchases of property, plant and equipment	(204,359)	(259,649)	55,290
Purchases of software	(19,916)	(25,467)	5,551
Sales of property, plant and equipment	11,022	4,061	6,961
Proceeds from sales and maturities of marketable and investment securities	1,981	18,125	(16,144)
Purchases of marketable and investment securities	(213)	(595)	382
(Increase) decrease in time deposits, net	(1,712)	(1,236)	(476)
Increase in investments in and advances to affiliated companies	-	(105)	105
Acquisitions of businesses, net of cash acquired	-	(1,183)	1,183
Proceeds from sale of businesses, net of cash and cash equivalents disposed of	-	6,926	(6,926)
Others	(18,516)	(9,277)	(9,239)
Net cash used in investing activities	(231,713)	(268,400)	36,687
Financing activities			
Proceeds from long-term debt	100,000	100,000	-
Repayments of long-term debt	(1,457)	(41,257)	39,800
Increase (decrease) in short-term debt, net	(15,072)	43,730	(58,802)
Cash dividends paid to shareholders	(42,187)	(42,170)	(17)
Subsidiaries' cash dividends paid to noncontrolling interests	(7)	(92)	85
Sales (purchase) of stock for treasury	(30,004)	(5)	(29,999)
Capital transactions with noncontrolling interests	(44)	141	(185)
Others	8	22	(14)
Net cash provided by financing activities	11,237	60,369	(49,132)
Effect of exchange rate changes on cash and cash equivalents	706	(2,349)	3,055
Net increase (decrease) in cash and cash equivalents	(24,688)	(11,233)	(13,455)
Cash and cash equivalents at beginning of period	170,553	172,111	(1,558)
Cash and cash equivalents at end of period	145,865	160,878	(15,013)

(4) Notes to Consolidated Financial Statements

(Note Relating to the Going Concern Assumption)

None.

(Segment Information)

1. Six months ended September 30

(A) Operating Segment Information

a. Revenue

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026		Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025		Change	
					Amount	%
Revenue:	Composition (%)		Composition (%)			
Healthcare	32.4	554,117	31.7	499,185	54,932	11.0
Electronics	15.2	259,621	13.3	209,466	50,155	23.9
Business Innovation	33.1	566,705	36.4	572,187	(5,482)	(1.0)
Imaging	19.3	331,071	18.5	291,525	39,546	13.6
Consolidated total	100.0	1,711,514	100.0	1,572,363	139,151	8.8

b. Expenses

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026	Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025	Change	
			Amount	%
R&D expenses				
Healthcare	27,411	26,198	1,213	4.6
Electronics	15,484	13,812	1,672	12.1
Business Innovation	31,456	27,936	3,520	12.6
Imaging	9,476	5,510	3,966	72.0
Subtotal	83,827	73,456	10,371	14.1
Corporate	2,422	3,849	(1,427)	(37.1)
Consolidated total	86,249	77,305	8,944	11.6
Other operating expenses				
Healthcare	523,339	449,306	74,033	16.5
Electronics	180,613	153,682	26,931	17.5
Business Innovation	535,813	512,887	22,926	4.5
Imaging	228,145	205,623	22,522	11.0
Subtotal	1,467,910	1,321,498	146,412	11.1
Corporate	16,187	15,074	1,113	7.4
Consolidated total	1,484,097	1,336,572	147,525	11.0

c. Operating Income

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026		Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025		Change	
					Amount	%
Operating Income (Loss):	Margin (%)		Margin (%)			
Healthcare	0.6	3,367	4.7	23,681	(20,314)	(85.8)
Electronics	24.5	63,524	20.0	41,972	21,552	51.3
Business Innovation	(0.1)	(564)	5.5	31,364	(31,928)	-
Imaging	28.2	93,450	27.6	80,392	13,058	16.2
Total		159,777		177,409	(17,632)	(9.9)
Corporate expenses etc.		(18,609)		(18,923)	314	-
Consolidated total	8.2	141,168	10.1	158,486	(17,318)	(10.9)

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Electronics:	Semiconductor materials, display materials, industrial equipment, fine chemicals, etc.
Business Innovation:	Solutions and services, digital MFPs, equipment and materials for graphic communications, inks and industrial inkjet printheads, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

d. Total Assets

Amount Unit: Millions of yen

	As of September 30, 2026	As of March 31, 2026	Change	
			Amount	%
Total assets:				
Healthcare	3,274,100	3,227,034	47,066	1.5
Electronics	807,582	821,265	(13,683)	(1.7)
Business Innovation	1,427,323	1,469,229	(41,906)	(2.9)
Imaging	473,040	423,126	49,914	11.8
Subtotal	5,982,045	5,940,654	41,391	0.7
Corporate	120,706	113,122	7,584	6.7
Consolidated total	6,102,751	6,053,776	48,975	0.8

e. Depreciation and amortization, and Capital expenditures

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026	Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025	Change	
			Amount	%
Depreciation and amortization:				
Healthcare	50,014	34,754	15,260	43.9
Electronics	15,574	14,738	836	5.7
Business Innovation	26,235	22,397	3,838	17.1
Imaging	9,872	7,418	2,454	33.1
Corporate	2,154	2,152	2	0.1
Consolidated total	103,849	81,459	22,390	27.5
Capital expenditures:				
Healthcare	156,000	229,885	(73,885)	(32.1)
Electronics	15,947	13,462	2,485	18.5
Business Innovation	29,289	31,783	(2,494)	(7.8)
Imaging	16,000	10,902	5,098	46.8
Corporate	3,453	2,185	1,268	58.0
Consolidated total	220,689	288,217	(67,528)	(23.4)

f. Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Six months ended September 30, 2026 From April 1, 2026 To September 30, 2026		Six months ended September 30, 2025 From April 1, 2025 To September 30, 2025		Change	
					Amount	%
Revenue:	Composition (%)		Composition (%)			
Domestic	31.2	533,354	35.0	549,953	(16,599)	(3.0)
Overseas:						
The Americas	21.0	358,925	19.8	310,606	48,319	15.6
Europe	18.5	317,196	17.4	273,657	43,539	15.9
Asia and others	29.3	502,039	27.9	438,147	63,892	14.6
Subtotal	68.8	1,178,160	65.0	1,022,410	155,750	15.2
Consolidated total	100.0	1,711,514	100.0	1,572,363	139,151	8.8

Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer’s location.

2. Three months ended September 30

(A) Operating Segment Information

Revenue

Amount Unit: Millions of yen

	Three months ended September 30, 2026 From July 1, 2026 To September 30, 2026		Three months ended September 30, 2025 From July 1, 2025 To September 30, 2025		Change	
					Amount	%
Revenue:	Composition (%)		Composition (%)			
Healthcare	33.6	297,293	32.9	270,714	26,579	9.8
Electronics	14.9	131,971	13.0	107,326	24,645	23.0
Business Innovation	33.2	293,462	36.3	298,624	(5,162)	(1.7)
Imaging	18.3	162,295	17.8	146,217	16,078	11.0
Consolidated total	100.0	885,021	100.0	822,881	62,140	7.6

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Electronics:	Semiconductor materials, display materials, industrial equipment, fine chemicals, etc.
Business Innovation:	Solutions and services, digital MFPs, equipment and materials for graphic communications, inks and industrial inkjet printheads, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

(B) Geographic Information

Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended September 30, 2026 From July 1, 2026 To September 30, 2026		Three months ended September 30, 2025 From July 1, 2025 To September 30, 2025		Change	
					Amount	%
Revenue:	Composition (%)		Composition (%)			
Domestic	31.6	279,626	35.6	293,081	(13,455)	(4.6)
Overseas:						
The Americas	20.8	183,659	18.9	155,285	28,374	18.3
Europe	19.1	168,753	18.1	149,098	19,655	13.2
Asia and others	28.6	252,983	27.4	225,417	27,566	12.2
Subtotal	68.4	605,395	64.4	529,800	75,595	14.3
Consolidated total	100.0	885,021	100.0	822,881	62,140	7.6

(Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity)

None.

(Significant Subsequent Events)

None.